Latest News
- Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
- Phase III IPATential150 Study Evaluating Ipatasertib in Combination with Abiraterone and Prednisone/Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer Meets One of Its Co-Primary Endpoint
More News Articles
- Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
- Phase III IPATential150 Study Evaluating Ipatasertib in Combination with Abiraterone and Prednisone/Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer Meets One of Its Co-Primary Endpoint
- Tecentriq in combination with chemotherapy meets primary endpoint, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
- Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lynparza for Metastatic Castration-Resistant Prostate Cancer with HRR-Related Gene Alterations
- Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against Sawai and Nichi-Iko
- Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Novartis’ MET inhibitor, Capmatinib for Non-Small Cell Lung Cancer with MET exon 14 Skipping Alterations
- Chugai and FRONTEO Enter into a License Agreement for AI-based Drug Discovery Support System
- Updated Data of Overall Survival and Safety from the ALEX Study for Chugai's Alecensa Presented at the 2020 American Society of Clinical Oncology (ASCO)
- Chugai Starts Online Distribution of a Voice Drama Program “Katarisiennes” by ex-Takarasiennes to Encourage People in Novel Coronavirus Outbreak
- New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN
- Support for Control of Novel Coronavirus in Japan
- Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Eli Lilly and Company
- Chugai and A*STAR Begin Joint Research on a Therapeutic Antibody to Fight COVID-19
- Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology
Company Events
5th Antibody Symposium in Biopolis, Singapore
March 5-6, 2018
One north Festival
August, 2017
CPR’s 5th Anniversary Party
November 14, 2016
BioPharma Asia Convention 2014
March 10-13, 2014
Biopolis 10th Anniversary Carnival
October 18, 2013
CPR’s 1st Anniversary Party
June 27, 2013
BioPharma Asia Convention 2013
March 19, 2013
4th Antibody Symposium in Biopolis, Singapore
November 14, 2016
3rd Antibody Symposium in Biopolis, Singapore
January 14, 2015
2nd Antibody Symposium in Biopolis, Singapore
September 10, 2013
1st Antibody Symposium in Biopolis, Singapore
September 17, 2012
Official Opening Ceremony
July 13, 2012